UBS analyst Eliana Merle maintains BioNTech (NASDAQ:BNTX) with a Neutral and raises the price target from $97 to $131.
UBS Maintains Neutral on BioNTech, Raises Price Target to $131
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.